Mengmeng (Margaret) Du, ScD

Assistant Attending Epidemiologist

Mengmeng (Margaret) Du, Assistant Attending Epidemiologist

Office Phone



Harvard University

Dr. Du carries out a wide breadth of population-based research to reduce the burden of colorectal, endometrial, and pancreatic cancers—particularly in underserved or understudied populations. She works with international research teams to understand tumor biology and identify individuals who could most benefit from risk-reducing lifestyle modifications, interventions, or early detection tools. To this end, Dr. Du studies colorectal cancer genomics and risk profiles in Nigeria through the African Research Group in Oncology (ARGO) as well as in European populations though large consortia and cohorts. She studies endometrial cancer genomics and risk, including factors that drive the 2-fold higher mortality in Black women, in the Epidemiology of Endometrial Cancer Consortium (E2C2)—for which she is principal investigator of the Data Coordinating Center. She also examines pancreatic cancer risk factors and early detection/surveillance and is principal investigator of the MSK Pancreatic Tumor Registry. Dr. Du studies telomere dynamics in various population-based data sources. Her work is supported by the National Cancer Institute, National Center for Advancing Translational Sciences, David M. Rubenstein Center for Pancreatic Cancer Research, Thompson Family Foundation, and generous MSK donors.

Beyond research, Dr. Du is dedicated to educating young scientists: She co-directs the MSK Quantitative Sciences Summer Undergraduate Research Experience (QSURE) and teaches Foundations of Epidemiology (NS6520) at Weill Cornell Medicine. She also serves on the Scientific Committee for the New York City Epidemiology Forum, co-chairs the E2C2 Executive Committee, and is Associate Editor for the international peer-reviewed journal Cancer Causes & Control.


Representative Publications

  1. Healthcare utilisation, cancer screening and potential barriers to accessing cancer care in rural South West Nigeria: a cross-sectional study. Sharma A, Alatise OI, O’Connell K, Ogunleye SG, Aderounmu AA, Samson ML, Wuraola F, Olasehinde O, Kingham TP, Du MBMJ Open. 2021;11:e040352.
  2. Determining Risk of Colorectal Cancer and Starting Age of Screening Based on Lifestyle, Environmental, and Genetic Factors. Jeon J, Du M, Schoen RE, …, Peters U, Hsu L, Colorectal Transdisciplinary Study and Genetics and Epidemiology of Colorectal Cancer Consortium. Gastroenterology. 2018;154(8):2152-2164.e19.
  3. Evaluation of Early-Life Factors and Early-Onset Colorectal Cancer Among Men and Women in the UK Biobank. Gausman V*, Liang PS* (joint lead author), O’Connell K, Kantor ED, Du M. Gastroenterology. 2022;162(3):981-983.e3
  4. Physical activity and risk of endometrial cancer in the Nurses’ Health Study. Du M, Kraft P, Eliassen AH, Giovannucci E, Hankinson SE, De Vivo I. Int J Cancer. 2014;134(11):2707-16.
  5. Shorter telomeres associate with a reduced risk of melanoma development. Nan H, Du M* (joint lead author), De Vivo I, Manson JE, Liu S, McTiernan A, Curb JD, Lessin LS, Bonner MR, Guo Q, Qureshi AA, Hunter DJ, Han J. Cancer Res. 2011;71(21):6758-63.

View a full listing of Mengmeng (Margaret) Du’s journal articles.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Mengmeng (Margaret) Du discloses the following relationships and financial interests:

No disclosures meeting criteria for time period

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures